rnai
therapeut
repres
fundament
new
way
treat
human
diseas
address
target
otherwis
undrugg
exist
medicin
discoveri
long
doublestrand
rna
dsrna
mediat
rnai
subsequ
demonstr
rnai
mediat
smallinterf
rna
sirna
oper
mammalian
spark
explos
research
uncov
new
mechan
gene
silenc
revolution
understand
endogen
mechan
gene
regul
provid
power
new
tool
biolog
research
drug
discoveri
first
vivo
evid
rnaibas
therapeut
efficaci
anim
diseas
model
ref
pace
drug
develop
rapid
three
phase
studi
investig
rnaibas
drug
agerel
macular
degener
amd
lead
caus
blind
respiratori
syncyti
viru
rsv
lead
caus
paediatr
hospit
unit
state
today
alreadi
complet
without
untoward
toxic
despit
promis
real
hurdl
need
overcom
translat
therapeut
potenti
rnai
clinic
realiti
import
mileston
clear
demonstr
efficaci
wellcontrol
human
clinic
studi
rnai
pathway
guid
small
rna
includ
sirna
microrna
mirna
latter
deriv
imperfectli
pair
noncod
hairpin
rna
structur
natur
transcrib
gene
silenc
induc
sirna
sequencespecif
cleavag
perfectli
complementari
messeng
rna
mrna
wherea
microrna
mediat
translat
repress
transcript
degrad
imperfectli
complementari
target
fig
endogen
pathway
rna
contain
stem
loop
short
hairpin
structur
encod
intragen
region
within
intron
process
nucleu
export
cytoplasm
precursor
molecul
call
cytoplasm
premicrorna
shorten
process
rnase
iii
enzym
call
dicer
produc
imperfectli
match
doublestrand
microrna
dicer
similarli
process
long
perfectli
match
dsrna
sirna
fig
multienzym
complex
includ
argonaut
also
known
rnainduc
silenc
complex
risc
bind
either
microrna
duplex
sirna
duplex
discard
one
strand
thought
passeng
sens
strand
cleav
case
sirna
releas
case
mirna
form
activ
complex
contain
guid
antisens
activ
complex
seek
bind
mrna
strand
bear
complementari
sequenc
inactiv
express
complementar
less
perfect
mirna
complex
block
translat
complementar
perfect
nearli
perfect
sirna
complex
cleav
mrna
strand
nucleotid
complementari
nucleotid
guid
strand
rel
fig
addit
translat
repress
mirna
may
also
mediat
mrna
degrad
cytoplasm
compart
known
process
bodi
pbodi
gene
silenc
mrna
cleavag
thought
particularli
potent
part
mrna
cleavag
lead
rapid
nucleolyt
degrad
rna
fragment
free
activ
risc
complex
seek
destroy
anoth
target
mrna
catalyt
goal
rnaibas
therapi
activ
select
mrna
cleavag
effici
gene
silenc
possibl
har
endogen
pathway
one
two
way
either
use
viral
vector
express
short
hairpin
rna
shrna
resembl
microrna
precursor
introduc
sirna
mimic
dicer
cleavag
product
cytoplasm
sirna
bypass
earlier
step
rnai
silenc
pathway
load
directli
onto
complex
although
deliveri
synthet
sirna
viral
deliveri
shrna
develop
potenti
rnaibas
therapeut
approach
articl
focus
sole
develop
synthet
sirna
drug
synthet
sirna
har
natur
occur
rnai
pathway
manner
consist
predict
thu
make
particularli
attract
therapeut
moreov
enter
rnai
pathway
later
sirna
less
like
interfer
gene
regul
endogen
consequ
sirna
class
rnai
therapeut
advanc
preclin
clinic
studi
vitro
select
initi
step
identifi
potent
lead
sirna
candid
start
bioinformat
design
involv
vitro
studi
determin
silenc
efficaci
verifi
unwant
offtarget
effect
absent
introduc
chemic
modif
need
improv
stabil
specif
overal
scheme
turn
sirna
drug
summar
fig
three
import
attribut
take
account
design
select
sirna
potenc
specif
nucleas
stabil
two
type
offtarget
effect
need
avoid
minim
silenc
gene
share
partial
homolog
sirna
immun
stimul
stem
recognit
certain
sirna
innat
immun
system
understand
molecular
structur
mechan
rnai
grown
issu
around
lead
sirna
select
better
understood
offtarget
effect
gener
mitig
possibl
rapidli
identifi
span
sever
week
month
potent
specif
stabl
vitro
activ
lead
sirna
candid
target
gene
interest
potenc
rnai
activ
mammalian
cell
introduc
sirna
mimic
dicercleav
endogen
microrna
sirna
identifi
silenc
gene
often
vitro
activ
nanomolar
lower
concentr
algorithm
predict
effect
sirna
base
common
featur
sirna
identifi
empir
test
avail
although
algorithm
increas
chanc
identifi
activ
sirna
imperfect
sometim
miss
potent
sirna
identifi
experiment
test
altern
use
algorithm
start
point
identifi
candid
sirna
test
tile
nucleotid
sequenc
mrna
code
region
experiment
select
group
candid
induc
effect
silenc
lowest
concentr
one
studi
suggest
slightli
longer
sirna
need
process
dicer
incorpor
risc
use
dicer
substrat
maintain
silenc
activ
although
longer
sirna
complic
synthes
could
increas
propens
activ
untoward
immun
load
risc
respect
sens
antisens
sirna
strand
strand
least
tightli
bound
favour
bind
deep
pocket
risc
becom
activ
strand
strand
select
fact
manipul
make
singl
nucleotid
substitut
end
duplex
alter
rel
bind
design
sirna
mismatch
intend
activ
strand
favour
incorpor
risc
may
possibl
increas
likelihood
identifi
potent
duplex
specif
rnaimedi
silenc
gene
express
highli
specif
evidenc
select
silenc
allel
contain
singl
nucleotid
nevertheless
sirna
also
recogn
interfer
express
mrna
share
partial
homolog
target
mrna
vitro
transcript
profil
shown
sirna
alter
mrna
level
offtarget
gene
addit
intend
target
gene
usual
chang
less
accur
assess
offtarget
silenc
would
requir
detail
proteom
analys
identifi
gene
tool
unbias
analysi
protein
express
less
develop
present
appli
examin
offtarget
silenc
surprisingli
mani
offtarget
gene
reduc
mrna
level
contain
region
complementari
one
two
strand
sirna
complementar
guid
strand
mrna
key
offtarget
silenc
critic
nucleotid
posit
two
eight
guid
strand
socal
seed
region
microrna
recognit
endogen
target
fig
accordingli
one
approach
minim
offtarget
effect
care
design
sirna
minim
exact
seed
pair
although
seed
region
seven
nucleotid
short
length
altern
chemic
modif
ribos
guid
strand
suppress
offtarget
effect
maintain
targetmrna
particular
singl
modif
nucleotid
suppress
offtarget
silenc
without
significantli
interf
ontarget
silenc
thu
bioinformat
design
andor
positionspecif
sequenceindepend
chemic
modif
use
reduc
sequencerel
offtarget
effect
maintain
effici
targetmrna
silenc
sirna
also
induc
potenti
unwant
effect
activ
innat
immun
respons
set
defenc
system
usual
use
combat
virus
one
pathway
involv
recognit
dsrna
serinethreonin
protein
kinas
pkr
review
ref
pathway
effici
trigger
dsrna
nucleotid
long
higher
concentr
howev
smaller
sirna
may
abl
activ
pathway
result
global
translat
blockad
cell
death
perhap
concern
potenti
activ
tolllik
receptor
tlr
especi
dsrna
receptor
plasmacytoid
dendrit
cell
trigger
product
type
interferon
proinflammatori
cytokin
induc
nuclear
much
way
certain
cpg
motif
antisens
oligonucleotid
mediat
immunostimul
interferon
induct
sirna
occur
princip
larg
found
endosom
immun
antigenpres
cell
fortun
bind
sequenc
specif
favour
gurich
sequenc
avoid
choos
sequenc
recogn
receptor
addit
work
requir
identifi
immunostimulatori
motif
determin
whether
receptor
might
also
involv
sever
approach
exist
circumv
immunostimulatori
properti
certain
sirna
duplex
candid
duplex
transfect
plasmacytoid
dendrit
cell
test
whether
induc
interferon
discard
moreov
presenc
modif
within
sirna
duplex
use
abrog
bind
abolish
immunostimulatori
modif
also
reduc
sequencedepend
offtarget
silenc
may
particularli
benefici
enhanc
sirna
target
specif
potenti
signal
could
also
evad
use
sirna
deliveri
strategi
avoid
cell
type
respons
immun
stimul
transport
sirna
directli
cytoplasm
therebi
avoid
tlr
activ
endosom
stabil
nake
sirna
degrad
human
plasma
halflif
convert
sirna
optim
drug
chemic
modif
prolong
sirna
halflif
without
jeopard
biolog
activ
investig
detail
start
point
effort
chemistri
alreadi
use
antisens
oligonucleotid
aptam
therapeut
instanc
introduct
phosphorothio
ps
backbon
linkag
protect
exonucleas
degrad
modif
provid
endonucleas
fig
respect
maintain
rnai
silenc
activ
exonucleasestabil
modif
well
toler
introduct
intern
sugar
modif
protect
endonucleas
also
gener
toler
depend
locat
modif
within
duplex
sens
strand
amen
modif
antisens
strand
nevertheless
use
simpl
welldescrib
modif
ps
possibl
instanc
stabil
sirna
duplex
maintain
silenc
activ
minim
modif
requir
stabil
particular
sirna
duplex
identifi
studi
degrad
fragment
plasma
therebi
avoid
toxic
associ
certain
oligonucleotid
chemistri
minim
chang
could
reduc
activ
inform
sirna
stabil
bodi
fluid
publish
need
consid
depend
applic
sirna
formul
differ
carrier
system
vivo
deliveri
may
protect
nucleas
digest
last
longer
nake
sirna
improv
nucleasest
especi
import
sirna
duplex
expos
nucleaserich
environ
blood
formul
use
excipi
confer
addit
nucleas
protect
might
expect
situat
nucleasestabil
sirna
show
improv
pharmacokinet
properti
situat
deliv
sirna
directli
less
nucleaserich
site
lung
deliv
sirna
conjunct
deliveri
agent
liposom
degre
nucleas
stabil
reduc
significantli
although
abil
sirna
duplex
reach
target
cell
intact
vital
import
whether
nucleas
protect
confer
measur
benefit
sirna
insid
cell
remain
determin
vitro
comparison
nake
sirna
versu
fulli
stabil
sirna
reveal
signific
differ
longev
mrna
studi
typic
carri
use
rapidli
divid
cell
dilut
due
cell
divis
intracellular
sirna
halflif
govern
durat
gene
howev
durabl
silenc
nondivid
cell
vitro
vivo
last
week
suggest
stabil
might
necessari
within
cell
recent
develop
fluoresc
reson
energi
transfer
techniqu
fret
studi
use
evalu
whether
nucleasestabil
enhanc
intracellular
activ
therapeut
consider
design
sirna
therapeut
purpos
consider
beyond
find
activ
target
sequenc
possibl
desir
identifi
target
sequenc
conserv
across
relev
speci
use
safeti
efficaci
studi
thu
enabl
develop
singl
drug
candid
research
stage
clinic
studi
much
progress
made
understand
attribut
identifi
activ
stabl
sirna
vitro
much
less
known
well
attribut
translat
vivo
activ
knowledg
sirna
specif
base
vitro
data
furthermor
rang
offtarget
gene
identifi
tissu
cultur
differ
dramat
depend
transfect
method
use
introduc
sirna
cell
mrna
express
profil
target
likewis
induct
innat
immun
respons
certain
sirna
celltyp
uncertainti
vivo
properti
practic
prudent
approach
identifi
sever
lead
candid
sirna
suitabl
subsequ
vivo
studi
select
librari
test
sirna
duplex
potent
specif
stabl
endogen
nucleas
lack
immunostimulatori
activ
vivo
deliveri
effect
deliveri
challeng
hurdl
remain
develop
rnai
broad
therapeut
platform
anim
studi
use
sirna
either
use
addit
formul
nake
sirna
deliv
sirna
formul
conjug
liposomelipoplex
complex
peptid
polym
antibodi
fig
challeng
local
direct
deliveri
elucid
tissu
site
local
deliv
sirna
test
ongo
clinic
studi
eye
amd
lung
rsv
infect
see
clinic
trial
section
detail
local
deliveri
direct
rnai
advantag
drug
dose
sirna
requir
efficaci
substanti
lower
inject
administ
near
target
tissu
direct
deliveri
might
also
reduc
undesir
system
side
effect
system
deliveri
sirna
target
tissu
deep
within
bodi
remain
challeng
although
recent
success
anim
model
section
review
differ
sirna
deliveri
approach
exampl
vivo
success
use
sirna
summar
tabl
sever
recent
public
offer
comprehens
review
nake
sirna
mani
report
describ
success
rnai
vivo
involv
direct
deliveri
nake
sirna
tissu
eye
lung
central
nervou
system
cn
tabl
understood
certain
cell
other
directli
take
sirna
cytoplasm
rnai
machineri
oper
use
term
nake
sirna
refer
deliveri
sirna
unmodifi
modifi
salin
simpl
excipi
dextros
eas
formul
administr
use
direct
deliveri
nake
sirna
tissu
make
attract
therapeut
approach
surprisingli
initi
develop
rnai
therapeut
focus
diseas
target
clinic
indic
amd
rsv
infect
allow
direct
administr
sirna
diseas
organ
ocular
deliveri
proofofconcept
sirna
efficaci
eye
first
demonstr
anim
model
ocular
neovascular
scar
use
salin
lipidbas
lipidformul
vascular
endotheli
growth
factor
vegf
sirna
reduc
laserinduc
choroid
neovascular
mous
model
scar
model
nonhuman
primat
intravitr
inject
salineformul
vegf
sirna
well
toler
intravitr
inject
salineformul
sirna
target
vegf
also
effect
reduc
area
ocular
neovascular
two
differ
mous
encourag
studi
laid
ground
work
clinic
test
sirna
target
vegf
pathway
amd
respiratori
deliveri
intranas
orotrach
administr
formul
sirna
result
effect
gene
silenc
lung
therapeut
benefit
number
pulmonari
diseas
model
studi
use
nake
sirna
either
salin
excipi
lung
surfact
formul
sirna
transfect
lipid
anoth
special
deliveri
carrier
sometim
dispens
howev
requir
dose
deliveri
certain
cell
type
lung
indic
might
improv
incorpor
sirna
carrier
one
studi
intranas
instil
sirna
either
unformul
complex
transfect
agent
transittko
direct
viral
gene
reduc
viral
load
rsv
parainfluenza
viru
two
relev
pathogen
paediatr
immunocompromis
patient
three
order
magnitud
use
dose
sirna
low
per
anim
observ
advers
patholog
featur
rsv
infect
elev
leukotrien
level
pulmonari
inflamm
clinic
sign
respiratori
distress
also
reduc
sirna
administr
protect
could
achiev
prophylaxi
treatment
paradigm
similarli
sirna
formul
administ
intranas
nonhuman
primat
model
sever
acut
respiratori
syndrom
sar
corona
viru
infect
significantli
reduc
interstiti
infiltr
patholog
chang
inhibit
viral
replic
studi
clearli
demonstr
potenti
rnai
therapeut
treat
viral
respiratori
infect
gene
silenc
local
deliv
sirna
lung
also
demonstr
studi
design
identifi
key
molecul
respons
lung
injuri
variou
model
acut
lung
injuri
ali
intranas
administr
sirna
target
haem
oxygenas
also
known
result
enhanc
apoptosi
ir
mous
model
demonstr
induct
gene
ir
induc
express
number
organ
intranas
administ
sirna
silenc
gene
express
lung
anoth
studi
haemorrhageinduc
septic
challeng
model
ali
show
sirna
target
keratinocytederiv
chemokin
kc
macrophageinflammatori
protein
also
known
administ
intratrach
decreas
lung
kc
mrna
approxim
reduc
local
interleukin
concentr
case
sirna
reduc
neutrophil
influx
interstiti
oedema
lung
silenc
fassirna
model
suppress
induct
fa
amelior
pulmonari
apoptosi
hyperoxiainduc
ali
intranas
administr
angiopoietin
sirna
salin
dramat
amelior
oxid
injuri
cell
death
inflamm
vascular
permeabl
bleomycininduc
lung
fibrosi
intranas
instil
sirna
target
discoidin
domain
receptor
reduc
protein
lung
attenu
lung
inflammatori
cell
infiltr
cytokin
studi
clearli
demonstr
potenti
direct
instil
nake
sirna
silenc
endogen
gene
lung
treat
pulmonari
diseas
cn
deliveri
direct
instil
sirna
salin
also
use
cn
valid
diseas
target
vivo
direct
administr
salineformul
sirna
intracerebroventricular
intrathec
intraparenchym
infus
result
silenc
specif
neuron
mrna
target
multipl
region
peripher
central
nervou
although
nake
unformul
sirna
dose
typic
requir
target
silenc
rodent
studi
high
mg
per
day
sirna
uptak
uneven
polym
lipidbas
deliveri
system
facilit
cellular
uptak
effect
vivo
dose
reduc
conjug
coval
conjug
sirna
target
molecul
use
deliv
sirna
cell
use
principl
celltypespecif
target
conjug
therapeut
fix
singl
compound
reduc
complex
chemic
manufactur
regulatori
perspect
conjug
especi
attract
sirnabas
drug
one
strand
duplex
activ
conjug
attach
sens
passeng
strand
without
disrupt
activ
activ
antisens
strand
conjug
place
either
sens
strand
although
instanc
also
toler
antisens
strand
date
sirna
conjug
made
use
lipophil
molecul
protein
peptid
aptam
conjug
cholesterol
previous
use
deliv
antisens
oligonucleotid
adapt
achiev
effect
vivo
silenc
intraven
inject
sirna
duplex
conjug
cholesterol
passeng
strand
target
apolipoprotein
b
apob
mice
silenc
apob
mrna
liver
jejunum
two
main
site
apob
express
concomitantli
apob
plasma
protein
drop
serum
cholesterol
fell
consist
biolog
function
apob
bind
cholesterol
cholesterol
conjug
critic
improv
pharmacokinet
vivo
cellular
uptak
unconjug
apob
sirna
rapidli
clear
inact
howev
experi
requir
rel
high
dose
mg
per
kg
sirna
cholesterol
conjug
report
prolong
circul
halflif
incorpor
conjug
circul
lipoprotein
particl
resist
filtrat
kidney
may
also
provid
protect
plasma
nucleas
sirnacontain
lipoprotein
complex
endocytos
cholesterol
receptor
present
cell
stoffel
person
commun
natur
ligand
directli
conjug
sirna
duplex
shown
facilit
deliveri
least
vitro
includ
membran
permeant
peptid
penetratin
robust
evid
improv
cellular
deliveri
conjug
still
lack
although
certain
natur
ligand
transferrin
folat
rgd
argglyasp
peptid
success
use
target
agent
sirna
formul
yet
thoroughli
investig
direct
sirna
conjug
final
sirna
conjug
small
molecul
bind
cellsurfac
receptor
present
limit
number
cell
theori
enhanc
drug
specif
reduc
requir
drug
concentr
evid
vivo
use
smallmolecul
sirna
conjug
far
publish
import
rememb
small
molecul
might
benefit
natur
ligand
conjug
cholesterol
facilit
sirna
incorpor
larger
plasma
protein
complex
evad
rapid
renal
excret
elimin
sirna
also
conjug
rna
aptam
deliveri
specif
cell
type
approach
advantag
therapeut
compos
entir
rna
recent
vitro
vivo
proofofconcept
shown
use
aptam
prostatespecif
membran
antigen
psma
cellsurfac
receptor
overexpress
prostat
cancer
cell
tumour
vascular
psma
aptam
either
directli
link
conjug
modular
streptavidin
promot
specif
cellular
uptak
rnaimedi
silenc
target
mrna
vitro
sirna
direct
surviv
gene
directli
link
psma
aptam
intern
cell
result
rnaimedi
targetmrna
silenc
cell
death
short
aptam
base
long
bind
wide
varieti
target
high
affin
possibl
design
sirnaaptam
chimera
longer
strand
base
within
rang
technic
commerci
feasibl
synthesi
longer
molecul
may
prove
difficult
synthes
commerci
scale
howev
although
short
aptam
conjug
work
local
deliveri
vivo
rapidli
clear
kidney
halflif
short
system
therapi
unless
incorpor
larger
particl
liposom
lipoplex
mani
drug
formul
liposom
improv
pharmacokinet
properti
decreas
toxic
liposom
vesicl
aqueou
compart
enclos
phospholipid
bilay
fuse
cell
membran
enhanc
drug
deliveri
cell
polar
drug
entrap
aqueou
centr
lipid
complex
nucleic
acid
form
amorph
particl
known
lipoplex
lipoplex
form
mix
sirna
commerci
transfect
agent
lipofectamin
transittko
liposom
develop
therapeut
deliveri
sirna
multicompon
nanoparticl
typic
compos
multipl
lipid
includ
cation
andor
fusogen
lipid
cholesterol
polyethylen
glycosyl
lipid
compon
import
role
fusogen
pharmacokinet
properti
liposom
fig
review
see
ref
liposom
lipoplex
extens
use
deliv
sirna
vitro
vivo
vitro
transfect
sirna
use
lipidbas
deliveri
agent
routin
laboratori
procedur
howev
primari
cell
type
lymphocyt
resist
lipidmedi
transfect
signific
success
also
demonstr
local
system
administr
sirna
use
liposom
lipoplex
intraven
inject
sirna
encapsul
stabl
nucleic
particl
silenc
apob
dramat
mice
nonhuman
importantli
singl
intraven
dose
mg
per
kg
snalpformul
sirna
cynomolgu
monkey
reduc
apob
mrna
liver
consequ
serum
cholesterol
lowdens
lipoprotein
reduc
respect
moreov
follow
singl
intraven
dose
mg
per
kg
snalpformul
sirna
gene
silenc
last
least
day
treatment
sirna
liposom
fairli
well
toler
experi
transient
increas
liver
enzym
seen
highest
dose
snalp
formul
also
effect
deliv
sirna
liver
anim
model
hepat
b
ebola
viru
whether
snalp
use
deliv
sirna
organ
liver
uncertain
system
administr
liposom
formul
lipoplex
result
deliveri
sirna
tissu
intraven
deliveri
cation
lipoplex
contain
tumour
necrosi
factor
tnf
sirna
specif
inhibit
tnf
product
knee
joint
allevi
diseas
mous
model
rheumatoid
wherea
sirna
formul
liposom
reduc
target
express
mous
lung
endothelia
expect
physiolog
summari
use
lipidbas
formul
system
deliveri
sirna
especi
liver
repres
one
promis
nearterm
opportun
develop
rnai
therapeut
local
inject
liposom
lipoplex
also
deliv
sirna
effect
target
cell
eye
nervou
system
tumour
subretin
inject
vegf
sirna
formul
transittko
reduc
choroid
neovascular
laserinduc
injuri
mous
subconjunctiv
inject
transform
growth
factor
receptor
ii
sirna
transittko
suppress
inflamm
fibrosi
mous
subconjunctiv
scar
intracrani
deliveri
lipidcomplex
sirna
target
viral
gene
protect
mice
fatal
japanes
enceph
viru
west
nile
viru
similarli
intrathec
administr
cation
lipid
formul
delta
opioid
receptor
dor
sirna
facilit
deliveri
specif
targetgen
silenc
spinal
cord
dorsal
root
block
antinocicept
dor
select
numer
public
report
success
antitumour
effect
follow
either
direct
system
tumour
inject
lipidformul
sirna
review
see
ref
one
recent
exampl
either
intratumour
intraperiton
inject
formul
sirna
direct
human
papilloma
viru
oncogen
inhibit
tumour
growth
suppress
express
induc
tumour
apoptosi
subcutan
cervic
cancer
use
lipidbas
deliveri
system
mani
direct
rnai
applic
must
assess
targetcellspecif
diseasespecif
manner
eye
lung
nervou
system
exampl
sirna
success
deliv
without
formul
agent
howev
exampl
formul
critic
area
increas
interest
direct
applic
lipoplex
sirna
mucos
surfac
vagina
intestin
intravagin
deliveri
lipidcomplex
sirna
direct
herp
simplex
viru
protect
mice
administ
andor
lethal
herp
viru
intravagin
administr
sirna
complex
lipofectamin
nake
sirna
also
specif
silenc
endogen
gene
genit
intrarect
administr
tnf
sirna
lipofectamin
also
reduc
tnf
level
attenu
colon
inflamm
descend
intravagin
intracolon
administr
sirna
use
lipidbas
deliveri
system
well
toler
mice
last
least
week
caus
inflamm
activ
interferon
rel
easi
access
mucos
site
larg
number
viral
infect
enter
bodi
mucos
portal
gener
toler
sirnalipid
formul
robust
vivo
deliveri
mucos
administr
lipidformul
sirna
fertil
area
develop
futur
rnai
therapeut
peptid
polym
sirna
also
complex
cation
peptid
polym
ionic
interact
neg
charg
phosphat
backbon
form
stabl
strategi
need
prevent
aggreg
control
particl
size
reproduc
manner
often
done
incorpor
molecul
polyethylen
glycol
peg
help
stabil
particl
prevent
aggreg
peg
group
also
improv
pharmacokinet
profil
particl
shield
posit
charg
surfac
stick
neg
charg
cell
membran
result
rapid
clearanc
circul
anoth
area
particl
engin
applic
liposom
polymer
nanoparticl
involv
use
target
nanoparticl
achiev
robust
vivo
target
particular
cell
type
molecul
rgd
introduc
particlebas
deliveri
vehicl
aid
sirna
target
cell
bear
natur
receptor
target
group
includ
antibodi
sugar
galactos
mannos
also
propos
target
sirna
specif
beyond
improv
particl
target
vivo
anoth
import
area
research
involv
increas
cytoplasm
deliveri
sirna
sever
phtrigger
polym
facilit
endosom
escap
could
incorpor
nanoparticl
data
alreadi
exist
show
one
may
improv
rnaimedi
silenc
target
deliveri
improv
cytoplasm
deliveri
nanoparticl
promis
field
activ
research
one
wide
studi
polym
deliveri
nucleic
acid
polyethylenimin
pei
pei
polym
synthet
linear
branch
structur
high
cation
charg
densiti
cation
polyplex
form
pei
sirna
thought
interact
cell
surfac
electrostat
endocytos
cell
disrupt
low
endosom
ph
endosom
escap
propos
occur
proton
spong
effect
wherebi
pei
enhanc
influx
proton
water
lead
endosom
swell
osmot
releas
polyplex
sirna
complex
report
show
therapeut
benefit
vivo
number
diseas
model
peicomplex
influenza
sirna
demonstr
antivir
effect
infect
wherea
similar
target
ebola
l
gene
result
partial
protect
lethal
ebola
infect
guinea
complex
target
human
epiderm
growth
factor
receptor
also
known
ref
shown
antitumour
activ
local
inject
peisirna
polyplex
target
nmethyldaspart
nmda
receptor
subunit
significantli
attenu
formalininduc
nocicept
signific
concern
use
pei
therapeut
deliveri
vehicl
extrem
toxic
seen
higher
dose
expand
safeti
margin
sever
group
optim
physic
structur
pei
improv
vivo
sirna
synthet
polyc
consist
histidin
polylysin
residu
also
evalu
deliveri
sirna
seem
improv
vitro
efficaci
compar
three
polym
approach
promis
vivo
sirna
data
chitosan
cyclodextrin
atelocollagen
proteasetr
collagen
nanoparticl
chitosan
welltoler
natur
biodegrad
polym
form
cation
complex
nucleic
acid
effect
vivo
rnai
deliveri
achiev
complex
lung
epitheli
cell
transgen
enhanc
green
fluoresc
protein
egfp
mice
intranas
subcutan
implant
breast
cancer
cell
intraven
transferrintarget
cyclodextrincontain
polyc
nanoparticl
silenc
oncogen
transferrin
receptorexpress
ewe
sarcoma
tumour
sirna
formul
nanoparticl
well
toler
nonhuman
system
administr
complex
mark
effect
subcutan
tumour
xenograft
well
bone
polym
approach
base
polyamidoamin
pamam
dendrim
poli
lacticcoglycol
acid
plga
nanoparticl
also
investig
vehicl
sirna
although
vivo
evid
rnaimedi
silenc
use
approach
remain
demonstr
cation
peptid
also
deliv
oligonucleotid
sever
peptidebas
gene
deliveri
system
form
peptid
mpg
peptid
cholesteryl
oligodarginin
promot
uptak
noncoval
bound
sirna
vitro
local
vivo
administr
vegf
sirna
led
tumour
regress
mous
peptidebas
approach
also
coupl
deliveri
system
liposom
enabl
target
deliveri
antibodi
antibodi
also
use
specif
target
deliveri
sirna
fusion
protein
deliv
noncoval
bound
sirna
hivenvelopeexpress
melanoma
cell
hivinfect
primari
cell
vitro
high
approach
protamin
fragment
bind
oligonucleotid
fab
fragment
hiv
envelop
antibodi
mediat
receptorspecif
bind
cell
express
hiv
envelop
protein
complex
administ
either
intratumour
intraven
specif
deliv
sirna
subcutan
tumour
vivo
retard
tumour
growth
singlechain
antibodi
breast
cancer
receptor
fuse
protamin
also
select
deliv
sirna
breast
cancer
cell
bear
receptor
recent
fusion
protein
target
human
white
blood
cell
activ
leukocyt
use
conform
sensit
singl
chain
antibodi
integrin
reveal
exquisit
select
target
strategi
vitro
studi
demonstr
potenti
antibodi
direct
sirna
select
cell
vivo
clinic
trial
rnai
rapidli
advanc
research
discoveri
clinic
trial
three
differ
rnai
therapeut
current
clinic
investig
sever
pois
enter
trial
soon
initi
trial
focus
wellvalid
therapeut
target
vegf
pathway
wet
form
amd
rsv
genom
treatment
rsv
infect
ophthalm
indic
histor
attract
oligonucleotidebas
therapeut
approv
oligonucleotidebas
drug
use
eye
treat
cmv
direct
inject
vitreal
caviti
effici
target
oligonucleotid
drug
retina
anoth
advantag
ocular
compart
rel
free
nucleas
compar
serum
permit
unmodifi
sirna
use
vitreal
caviti
howev
exonucleas
stabil
chemistri
dramat
improv
persist
intact
sirna
follow
intravitr
inject
alnylam
unpublish
result
eas
intraocular
drug
deliveri
combin
clinic
valid
vegf
therapeut
target
prolif
vascular
retinopathi
led
rapid
develop
sever
rnai
therapeut
intravitr
inject
unmodifi
sirna
target
vegfa
splice
isoform
complet
phase
ii
trial
patient
seriou
progress
wet
amd
report
provid
doserel
benefit
sever
endpoint
includ
near
vision
lesion
size
acuiti
pharmaceut
press
releas
also
test
efficaci
diabet
macular
oedema
phase
ii
trial
began
earli
acuiti
pharmaceut
press
releas
chemic
modifi
sirna
target
vegf
receptor
complet
phase
trial
patient
wet
amd
report
well
toler
also
report
stabil
improv
visual
acuiti
subset
patient
sirna
pharmaceut
press
releas
mani
advantag
deliv
sirna
therapeut
directli
lung
target
lung
epitheli
cell
lung
epitheli
cell
capabl
nake
sirna
uptak
rnai
mediat
moreov
local
lung
environ
also
rel
nucleasefre
compar
serum
deliveri
lung
inhal
noninvas
directli
target
tissu
epithelium
improv
drug
concentr
target
tissu
without
firstpass
metabol
reduc
drug
dose
decreas
likelihood
system
side
effect
mani
instanc
nake
sirna
salin
seem
effect
approach
optim
lung
deliveri
may
need
develop
differ
indic
first
pulmonari
studi
direct
treat
rsv
seriou
neonat
respiratori
infect
two
phase
intranas
trial
sirna
target
viral
nucleocapsid
gene
complet
healthi
adult
volunt
found
safe
well
toler
alnylam
pharmaceut
press
releas
clinic
develop
progress
experiment
infect
studi
ongo
summari
rnai
advanc
research
discoveri
clinic
trial
lightn
speed
nobelpr
win
discoveri
show
long
dsrna
could
silenc
gene
express
caenorhabd
public
show
short
synthet
sirna
could
induc
rnai
mammalian
present
day
three
differ
rnai
therapeut
human
clinic
trial
rnai
revolut
fundament
chang
understand
gene
express
regul
provid
power
new
tool
biolog
research
drug
discoveri
open
way
new
type
therapeut
potenti
treat
wide
array
diseas
princip
challeng
remain
achiev
broadest
applic
rnai
therapeut
hurdl
deliveri
main
barrier
success
rnai
deliveri
vivo
involv
achiev
proper
pharmacokinet
ensur
drug
exposur
relev
target
cell
type
har
mechan
promot
cellular
uptak
releas
drug
cytoplasm
progress
made
front
use
coval
conjug
noncoval
complex
nanoparticl
target
deliveri
yet
optim
cell
type
tissu
solut
probabl
need
tailor
target
cell
type
diseas
indic
identifi
optim
deliveri
solut
use
report
system
either
endogen
celltyp
specif
gene
transgen
could
greatli
expedit
process
likewis
optim
formul
vital
key
paramet
efficaci
safeti
assess
parallel
rapidli
arriv
formul
greatest
therapeut
window
challeng
sirna
deliveri
met
possibl
advanc
rnai
therapeut
rapidli
clinic
studi
mani
diseas
includ
remain
untreat
poorli
treat
convent
drug
ongo
clinic
trial
sirna
drug
amd
rsv
infect
first
test
ground
whether
rnai
therapeut
live
potenti
revolutionari
new
class
drug
